8 results were returned
A majority postulates a new "outward presentation test" to deal with the infringement of second medical use patents.
As the development of vaccines against COVID-19 is progressing, the question becomes urgent who will be liable if a vaccine is marketed and will cause unexpected adverse effects as a result of the requested speed and ...
Globally, many companies are (again) affected by significant decline in business and/or closures as a result of measures taken by governments to deal with the coronavirus. Many of these companies have some form of ...
European Medicines Agency (EMA) had communicated to third parties (with some omissions), information contained in toxicological test reports and clinical trial reports obtained in a MA application file on the grounds ...
Earlier this year the High Court agreed with the Canary Wharf Group that Brexit did not constitute an event which would frustrate its 25 year lease with the EMA.
Our London disputes team is delighted to provide you with the latest edition of our Dispute Resolution bulletin featuring articles on topical dispute resolution issues, recent legal developments and an introduction as ...
The Court of Justice provided guidance for the antitrust assessment of agreements between competitors in the pharmaceutical sector. The Court's judgment is relevant because it addresses fundamental issues that have been ...
On 2 June, the Commission launched a public consultation on its forthcoming Digital Services Act plus a New Competition Tool and is requesting feedback on roadmaps including one on ex ante regulatory instruments for ...
DEFAULT DEFAULT Most Relevant Alphabetical Chronological Go
REFINE RESULTS: